296 related articles for article (PubMed ID: 38390969)
1. Xenograft and organoid models in developing precision medicine for gastric cancer (Review).
Xu J; Yu B; Wang F; Yang J
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38390969
[TBL] [Abstract][Full Text] [Related]
2. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
3. Gastric organoids-an in vitro model system for the study of gastric development and road to personalized medicine.
Seidlitz T; Koo BK; Stange DE
Cell Death Differ; 2021 Jan; 28(1):68-83. PubMed ID: 33223522
[TBL] [Abstract][Full Text] [Related]
4. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.
Qu S; Xu R; Yi G; Li Z; Zhang H; Qi S; Huang G
Mol Biomed; 2024 Feb; 5(1):6. PubMed ID: 38342791
[TBL] [Abstract][Full Text] [Related]
5. Gastric Organoids: Progress and Remaining Challenges.
Pang MJ; Burclaff JR; Jin R; Adkins-Threats M; Osaki LH; Han Y; Mills JC; Miao ZF; Wang ZN
Cell Mol Gastroenterol Hepatol; 2022; 13(1):19-33. PubMed ID: 34547535
[TBL] [Abstract][Full Text] [Related]
6. A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.
Yan HHN; Siu HC; Law S; Ho SL; Yue SSK; Tsui WY; Chan D; Chan AS; Ma S; Lam KO; Bartfeld S; Man AHY; Lee BCH; Chan ASY; Wong JWH; Cheng PSW; Chan AKW; Zhang J; Shi J; Fan X; Kwong DLW; Mak TW; Yuen ST; Clevers H; Leung SY
Cell Stem Cell; 2018 Dec; 23(6):882-897.e11. PubMed ID: 30344100
[TBL] [Abstract][Full Text] [Related]
7. Challenges, applications and future directions of precision medicine in prostate cancer - the role of organoids and patient-derived xenografts.
Joshi A; Roberts MJ; Alinezhad S; Williams ED; Vela I
BJU Int; 2020 Jul; 126(1):65-72. PubMed ID: 32383524
[TBL] [Abstract][Full Text] [Related]
8. Use of conditional reprogramming cell, patient derived xenograft and organoid for drug screening for individualized prostate cancer therapy: Current and future perspectives (Review).
Cao J; Chan WC; Chow MSS
Int J Oncol; 2022 May; 60(5):. PubMed ID: 35322860
[TBL] [Abstract][Full Text] [Related]
9. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
Kopper O; de Witte CJ; Lõhmussaar K; Valle-Inclan JE; Hami N; Kester L; Balgobind AV; Korving J; Proost N; Begthel H; van Wijk LM; Revilla SA; Theeuwsen R; van de Ven M; van Roosmalen MJ; Ponsioen B; Ho VWH; Neel BG; Bosse T; Gaarenstroom KN; Vrieling H; Vreeswijk MPG; van Diest PJ; Witteveen PO; Jonges T; Bos JL; van Oudenaarden A; Zweemer RP; Snippert HJG; Kloosterman WP; Clevers H
Nat Med; 2019 May; 25(5):838-849. PubMed ID: 31011202
[TBL] [Abstract][Full Text] [Related]
10. Gastric cancer patient-derived organoids model for the therapeutic drug screening.
Xu J; Gong J; Li M; Kang Y; Ma J; Wang X; Liang X; Qi X; Yu B; Yang J
Biochim Biophys Acta Gen Subj; 2024 Apr; 1868(4):130566. PubMed ID: 38244703
[TBL] [Abstract][Full Text] [Related]
11. Personalized Cancer Medicine: An Organoid Approach.
Aboulkheyr Es H; Montazeri L; Aref AR; Vosough M; Baharvand H
Trends Biotechnol; 2018 Apr; 36(4):358-371. PubMed ID: 29366522
[TBL] [Abstract][Full Text] [Related]
12. Human gastric cancer modelling using organoids.
Seidlitz T; Merker SR; Rothe A; Zakrzewski F; von Neubeck C; Grützmann K; Sommer U; Schweitzer C; Schölch S; Uhlemann H; Gaebler AM; Werner K; Krause M; Baretton GB; Welsch T; Koo BK; Aust DE; Klink B; Weitz J; Stange DE
Gut; 2019 Feb; 68(2):207-217. PubMed ID: 29703791
[TBL] [Abstract][Full Text] [Related]
13. Establishment of Patient-Derived Gastric Cancer Organoid Model From Tissue Obtained by Endoscopic Biopsies.
Song H; Park JY; Kim JH; Shin TS; Hong SA; Huda MN; Kim BJ; Kim JG
J Korean Med Sci; 2022 Jul; 37(28):e220. PubMed ID: 35851862
[TBL] [Abstract][Full Text] [Related]
14. Organoid Cultures Derived From Patients With Papillary Thyroid Cancer.
Chen D; Tan Y; Li Z; Li W; Yu L; Chen W; Liu Y; Liu L; Guo L; Huang W; Zhao Y
J Clin Endocrinol Metab; 2021 Apr; 106(5):1410-1426. PubMed ID: 33524147
[TBL] [Abstract][Full Text] [Related]
15. Establishing Pure Cancer Organoid Cultures: Identification, Selection and Verification of Cancer Phenotypes and Genotypes.
Wallaschek N; Niklas C; Pompaiah M; Wiegering A; Germer CT; Kircher S; Brändlein S; Maurus K; Rosenwald A; Yan HHN; Leung SY; Bartfeld S
J Mol Biol; 2019 Jul; 431(15):2884-2893. PubMed ID: 31150736
[TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
[TBL] [Abstract][Full Text] [Related]
17. A synopsis of prostate organoid methodologies, applications, and limitations.
Gleave AM; Ci X; Lin D; Wang Y
Prostate; 2020 May; 80(6):518-526. PubMed ID: 32084293
[TBL] [Abstract][Full Text] [Related]
18. Tumor organoids: applications in cancer modeling and potentials in precision medicine.
Xu H; Jiao D; Liu A; Wu K
J Hematol Oncol; 2022 May; 15(1):58. PubMed ID: 35551634
[TBL] [Abstract][Full Text] [Related]
19. Emerging organoid models: leaping forward in cancer research.
Fan H; Demirci U; Chen P
J Hematol Oncol; 2019 Dec; 12(1):142. PubMed ID: 31884964
[TBL] [Abstract][Full Text] [Related]
20. Xenograft and organoid model systems in cancer research.
Bleijs M; van de Wetering M; Clevers H; Drost J
EMBO J; 2019 Aug; 38(15):e101654. PubMed ID: 31282586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
